NEW YORK, December 22, 2016 /PRNewswire/ --
Stock-Callers.com is currently reviewing the performances of the following Biotech equities: Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Intrexon Corp. (NYSE: XON), Rexahn Pharmaceuticals Inc. (NYSEMKT: RNN), and Tesaro Inc. (NASDAQ: TSRO). These companies belong to the Healthcare sector which weighed on the broader US markets on Wednesday, December 21st, 2016, with the NYSE Health Care Index retreating about 0.4%, and shares of health care companies in the S&P 500 declining about 0.5% as a group. Learn more about these stocks by downloading their comprehensive and free reports at:
At the close on Wednesday, shares in Tustin, California headquartered Peregrine Pharmaceuticals Inc. saw a slight decline of 0.32%, ending the day at $0.31. The stock recorded a trading volume of 1.76 million shares, which was above its three months average volume of 1.51 million shares. The Company's shares are trading below their 50-day moving average by 5.47%. Moreover, shares of Peregrine Pharma, which researches and develops monoclonal antibodies for the treatment of cancer in the US, have a Relative Strength Index (RSI) of 45.13.
On December 12th, 2016, Peregrine Pharma reported that contract manufacturing revenue from Avid's clinical and commercial biomanufacturing services provided to its third-party customers increased to $23,370,000 for Q2 FY17 compared to $9,523,000 for Q2 FY16. The Company's consolidated net loss attributed to common stockholders was $5,498,000 or $0.02 per share, for Q2 FY17 compared to a net loss attributed to common stockholders of $14,578,000, or $0.07 per share, for Q2 FY16. Peregrine Pharma reported $49,055,000 in cash and cash equivalents as of October 31st, 2016, compared to $61,412,000 at fiscal year ended April 30th, 2016. PPHM complete research report is just a click away and free at:
Shares in Germantown, Maryland-based Intrexon Corp. ended the day 4.00% lower at $26.13 with a total trading volume of 1.14 million shares. The stock is trading below its 50-day moving average by 7.81%. Shares of the Company, which operates in the synthetic biology field in the US, have an RSI of 36.13.
On December 13th, 2016, Intrexon Corp. announced initial studies have validated the efficacy of dsRNA for insect control applications using its proprietary ActoBiotics™ platform. With this achievement, Intrexon's collaboration with a leading global agricultural company advances to its next phase of development for biological crop protection solutions. The complimentary report on XON can be downloaded at:
On Wednesday, shares in Rockville, Maryland-based Rexahn Pharmaceuticals Inc. finished flat at $0.15 with a total trading volume of 553,419 shares. The stock is trading below its 50-day moving average by 9.44%. Shares of the Company, which discovers, develops, and commercializes treatments for cancer, have an RSI of 38.79.
As per a SEC filing dated November 25th, 2016, Rexahn Pharmaceuticals set on November 22nd, 2016, the date of its 2017 Annual Meeting of Stockholders of the Company as April 11th, 2017. Sign up for your complimentary research report on RNN at:
Waltham, Massachusetts headquartered Tesaro Inc.'s shares recorded a trading volume of 627,397 shares at the end of yesterday's session. The stock closed the day 0.25% higher at $136.80. The Company's shares have advanced 1.74% in the last one month, 26.17% in the previous three months, and 161.48% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.25% and 65.42%, respectively. Additionally, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US and internationally, have an RSI of 56.06.
On December 20th, 2016, TESARO announced that the US Food and Drug Administration (FDA) has granted Priority Review for the niraparib New Drug Application. Niraparib is a PARP inhibitor that is being evaluated as a potential new treatment option for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following response to platinum-based chemotherapy. The FDA has established a target action date under the Prescription Drug User Fee Act of June 30th, 2017, and is not currently planning to hold an advisory committee meeting to discuss this application. Get free access to your research report on TSRO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA